Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Quick Stats
Apr 02, 202655.7
AI Score
HOLD0.05
Volume Ratio
May 12, 2026
Next Earnings
15
+ve Days (30d)
13
-ve Days (30d)
RNA Stock Summary
Last updated Apr 02, 2026
RNA is currently trading at $13.41, positioned below its 200-day moving average of $50.27, suggesting bearish momentum. The stock has a 52-week range of $11.95 to $73.06.
Technical Analysis: The 50-day moving average stands at $43.39, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 11.671, suggesting the stock is oversold and potentially undervalued.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.113, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates RNA at 55.7/100 with a HOLD recommendation.
RNA (Avidity Biosciences, Inc. Common Stock) Indicators
Last updated Apr 02, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 11.671 |
| CMF (20) | -0.113 |
| ROC (10) | 7.25 |
| ADX (14) | 77.757 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -7.91 |
| AROONOSC (14) | -28.571 |
| WILLAMS %R (14) | -18.627 |
| MFI (14) | 58.896 |
RNA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
RNA Price vs Max Options Open Interest
RNA Max Change In Options Open Interest
RNA Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RNA Daily Out of Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RNA Daily In the Money Options - Sort by Max open Interest (near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
RNA Most Active Options by Volume(near term)
2nd April 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Avidity Biosciences, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
RNA Moving Averages Analysis
RNA (Avidity Biosciences, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Apr 02, 2026
| Days | MA |
|---|---|
| 10 | 13.28 |
| 20 | 13.63 |
| 30 | 23.81 |
| 50 | 43.39 |
| 100 | 57.51 |
| 200 | 50.27 |
RNA Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 207.4 million |
| Earnings/Share ($) | -4.48 |
| Net Proft Margin (%) | -2.6588 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -4.14 |
| EPS Estimate Next Year ($) | -4.62 |
| WallStreet Target Price ($) | 25 |
| Most Recent Quarter |